Legend Biotech Says Five-Year Carvykti Data Show 50% of Patients Remained Progression-Free and Alive
MT Newswires Live
Sep 25
Legend Biotech (LEGN) reported Friday that five-year follow-up data from cohort A of the Cartitude-2 study evaluating Carvykti showed 10 of 20 patients with relapsed or refractory multiple myeloma remained alive and progression-free without maintenance therapy.
The findings suggest that earlier use of Carvykti may increase the likelihood of achieving durable, treatment-free remission, the company said.
The five-year overall survival rate was 69.2%, while median overall survival had not been reached at the time of the analysis, Legend Biotech said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.